Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide

Anna Angona, Beatriz Bellosillo, Alberto Alvarez-Larrán, Luz Martínez-Avilés, Laura Camacho, Silvia Pairet, Maria Concepción Fernández-Rodriguez, Àgueda Ancochea, Carles Besses

    Research output: Contribution to journalArticleResearchpeer-review

    17 Citations (Scopus)

    Abstract

    JAK2V617F allele burden was prospectively measured in polycythemia vera (PV, n=52) and essential thrombocythemia (ET, n=39) patients receiving hydroxycarbamide (HC) and analyzed according to JAK2 46/1 haplotype and genotype of SLC14A1, SLC14A2 and ARG2 urea transporters. Molecular response (MR) was obtained in 68.7% and 38.9% of PV patients with GG and AA or GA genotype in SLC14A2, respectively (p=0.07). No significant differences were observed neither in PV nor in ET according to JAK2 46/1 haplotype, SLC14A1 and ARG2. In conclusion, JAK2 46/1 haplotype does not influence MR in HC treated patients and urea transporters polymorphisms display a minimal effect. © 2013 Elsevier Ltd.
    Original languageEnglish
    Pages (from-to)917-921
    JournalLeukemia Research
    Volume37
    Issue number8
    DOIs
    Publication statusPublished - 1 Aug 2013

    Keywords

    • Essential thrombocythemia
    • Hydroxycarbamide
    • Molecular response
    • Polycythemia vera

    Fingerprint

    Dive into the research topics of 'Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide'. Together they form a unique fingerprint.

    Cite this